Islet Sciences is developing first-in-class immune-modulating drugs that protect insulin-producing beta-cells from cytokines responsible for cell destruction. IL-12 and STAT 4 activation are important pathways linked to inflammatory damage to insulin producing cells. Islet Sciences is developing a next generation of orally bioavailable immune modulators against these key targets for the promise of providing a new therapeutic approach to treat type 1 or type 2 diabetes. These compounds were screened in vitro for their ability to provide beta cell protection against cytokines and preservation of insulin secretion. Three Lead compounds have been identified and are being progressed in pre-clinical studies. These next generation compounds will have better oral bioavailability and efficacy than LSF (left), offering the promise of providing a new therapeutic approach to treat type 1 or type 2 diabetes. Additional studies show that C-9 also directly reduces liver fibrosis in a Non-alcoholic Steatohepatitis preclinical model.


  • Small molecule that blocks inflammatory actions of cytokines that destroy insulin-producing beta cells
  • potential lead indications include:
    1. Adjunct therapy for islet cell (or other cellular) transplantation to reverse Type 1 diabetes Encapsulated Islets: 82.3±6%
      Reversing or arresting progression of Type 1 diabetes, Latent Autoimmune Diabetes of Adults (LADA) and insulin-using Type 2 diabetes
      Treatment of diabetic nephropathy and diabetic retinopathy


  • IL-12 activates key inflammatory pathway



  • Two open INDs
  • 5 Phase I trials completed involving 51 healthy subjects
    1. LSF was well tolerated
      No subject experienced a serious adverse event
  • CMC package to FDA
  • Toxicology package for IND
  • Uses for athrosclerosis, diabetes and kidney disease